StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 25 Jun 2026 11:52:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Imagion Biosystems raises AU$3.75M after FDA clears Phase 2 trial http://www.streetinsider.com/FDA/Imagion+Biosystems+raises+AU%243.75M+after+FDA+clears+Phase+2+trial/26690357.html <p>Imagion Biosystems, Ltd. (ASX: IBX) has secured AU$3.75M (US$2.59M) in new capital following FDA clearance of its investigational new drug application for a Phase 2 clinical trial of its MagSense® imaging agent in HER2+ breast cancer.</p> <p>The raise was led by CPS Capital Group Pty Ltd in a two-tranche placement. Tranche 1 involves the placement of 49.3 million new shares at AU$0.012 per share, totaling AU$592,000, using the company's existing placement capacity. Tranche 2 covers the remaining balance of approximately AU$3.2 million and is subject to shareholder approval at an extraordinary general meeting.</p> <p>The company said it has begun trial activation activities http://www.streetinsider.com/FDA/Imagion+Biosystems+raises+AU%243.75M+after+FDA+clears+Phase+2+trial/26690357.html Thu, 25 Jun 2026 11:52:13 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems raises AU$3.75M after FDA clears Phase 2 trial http://www.streetinsider.com/FDA/Imagion+Biosystems+raises+AU%243.75M+after+FDA+clears+Phase+2+trial/26690357.html <p>Imagion Biosystems, Ltd. (ASX: IBX) has secured AU$3.75M (US$2.59M) in new capital following FDA clearance of its investigational new drug application for a Phase 2 clinical trial of its MagSense® imaging agent in HER2+ breast cancer.</p> <p>The raise was led by CPS Capital Group Pty Ltd in a two-tranche placement. Tranche 1 involves the placement of 49.3 million new shares at AU$0.012 per share, totaling AU$592,000, using the company's existing placement capacity. Tranche 2 covers the remaining balance of approximately AU$3.2 million and is subject to shareholder approval at an extraordinary general meeting.</p> <p>The company said it has begun trial activation activities http://www.streetinsider.com/FDA/Imagion+Biosystems+raises+AU%243.75M+after+FDA+clears+Phase+2+trial/26690357.html Thu, 25 Jun 2026 11:52:13 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems raises AU$3.75M after FDA clears Phase 2 trial http://www.streetinsider.com/FDA/Imagion+Biosystems+raises+AU%243.75M+after+FDA+clears+Phase+2+trial/26690357.html <p>Imagion Biosystems, Ltd. (ASX: IBX) has secured AU$3.75M (US$2.59M) in new capital following FDA clearance of its investigational new drug application for a Phase 2 clinical trial of its MagSense® imaging agent in HER2+ breast cancer.</p> <p>The raise was led by CPS Capital Group Pty Ltd in a two-tranche placement. Tranche 1 involves the placement of 49.3 million new shares at AU$0.012 per share, totaling AU$592,000, using the company's existing placement capacity. Tranche 2 covers the remaining balance of approximately AU$3.2 million and is subject to shareholder approval at an extraordinary general meeting.</p> <p>The company said it has begun trial activation activities http://www.streetinsider.com/FDA/Imagion+Biosystems+raises+AU%243.75M+after+FDA+clears+Phase+2+trial/26690357.html Thu, 25 Jun 2026 11:52:13 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems raises AU$3.75M after FDA clears Phase 2 trial http://www.streetinsider.com/FDA/Imagion+Biosystems+raises+AU%243.75M+after+FDA+clears+Phase+2+trial/26690357.html <p>Imagion Biosystems, Ltd. (ASX: IBX) has secured AU$3.75M (US$2.59M) in new capital following FDA clearance of its investigational new drug application for a Phase 2 clinical trial of its MagSense® imaging agent in HER2+ breast cancer.</p> <p>The raise was led by CPS Capital Group Pty Ltd in a two-tranche placement. Tranche 1 involves the placement of 49.3 million new shares at AU$0.012 per share, totaling AU$592,000, using the company's existing placement capacity. Tranche 2 covers the remaining balance of approximately AU$3.2 million and is subject to shareholder approval at an extraordinary general meeting.</p> <p>The company said it has begun trial activation activities http://www.streetinsider.com/FDA/Imagion+Biosystems+raises+AU%243.75M+after+FDA+clears+Phase+2+trial/26690357.html Thu, 25 Jun 2026 11:52:13 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems raises AU$3.75M after FDA clears Phase 2 trial http://www.streetinsider.com/FDA/Imagion+Biosystems+raises+AU%243.75M+after+FDA+clears+Phase+2+trial/26690357.html <p>Imagion Biosystems, Ltd. (ASX: IBX) has secured AU$3.75M (US$2.59M) in new capital following FDA clearance of its investigational new drug application for a Phase 2 clinical trial of its MagSense® imaging agent in HER2+ breast cancer.</p> <p>The raise was led by CPS Capital Group Pty Ltd in a two-tranche placement. Tranche 1 involves the placement of 49.3 million new shares at AU$0.012 per share, totaling AU$592,000, using the company's existing placement capacity. Tranche 2 covers the remaining balance of approximately AU$3.2 million and is subject to shareholder approval at an extraordinary general meeting.</p> <p>The company said it has begun trial activation activities http://www.streetinsider.com/FDA/Imagion+Biosystems+raises+AU%243.75M+after+FDA+clears+Phase+2+trial/26690357.html Thu, 25 Jun 2026 11:52:13 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial http://www.streetinsider.com/Press+Releases/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html <p> MELBOURNE, Australia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.imagionbiosystems.com&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=Imagion+Biosystems%2C+Ltd.+%28ASX%3A+IBX%29&index=1&md5=681842b3cfdaae4cd61f68c1e5edcaa5" shape="rect">Imagion Biosystems, Ltd. (ASX: IBX)</a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fnews%2Fimagion-biosystems-ind-application-for-phase-2-trial-clears-fda-review%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=the+FDA%26%238217%3Bs+clearance+of+the+company%26%238217%3Bs+IND+application&index=2&md5=41332b86bd19bfc3167a8b2f5b89c87d" shape="rect">the FDA’s clearance of the company’s IND application</a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Four-technology%2Fmagsense-technology%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=MagSense%26%23174%3B&index=3&md5=5d7326bd693feba178dbdd8ba2d94fec" shape="rect">MagSense®</a> imaging agent in HER2+ breast cancer. The company has already begun <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fclinical-trials%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=trial+activation+activities&index=4&md5=6f0e1d9ad5421e49076926e889cb0b9e" shape="rect">trial activation activities</a> and expects to begin patient recruitment later this year. </p><p> “We are very pleased with the strong demand we saw http://www.streetinsider.com/Press+Releases/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html Thu, 25 Jun 2026 11:51:00 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial http://www.streetinsider.com/Press+Releases/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html <p> MELBOURNE, Australia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.imagionbiosystems.com&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=Imagion+Biosystems%2C+Ltd.+%28ASX%3A+IBX%29&index=1&md5=681842b3cfdaae4cd61f68c1e5edcaa5" shape="rect">Imagion Biosystems, Ltd. (ASX: IBX)</a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fnews%2Fimagion-biosystems-ind-application-for-phase-2-trial-clears-fda-review%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=the+FDA%26%238217%3Bs+clearance+of+the+company%26%238217%3Bs+IND+application&index=2&md5=41332b86bd19bfc3167a8b2f5b89c87d" shape="rect">the FDA’s clearance of the company’s IND application</a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Four-technology%2Fmagsense-technology%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=MagSense%26%23174%3B&index=3&md5=5d7326bd693feba178dbdd8ba2d94fec" shape="rect">MagSense®</a> imaging agent in HER2+ breast cancer. The company has already begun <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fclinical-trials%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=trial+activation+activities&index=4&md5=6f0e1d9ad5421e49076926e889cb0b9e" shape="rect">trial activation activities</a> and expects to begin patient recruitment later this year. </p><p> “We are very pleased with the strong demand we saw http://www.streetinsider.com/Press+Releases/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html Thu, 25 Jun 2026 11:51:00 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial http://www.streetinsider.com/Press+Releases/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html <p> MELBOURNE, Australia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.imagionbiosystems.com&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=Imagion+Biosystems%2C+Ltd.+%28ASX%3A+IBX%29&index=1&md5=681842b3cfdaae4cd61f68c1e5edcaa5" shape="rect">Imagion Biosystems, Ltd. (ASX: IBX)</a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fnews%2Fimagion-biosystems-ind-application-for-phase-2-trial-clears-fda-review%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=the+FDA%26%238217%3Bs+clearance+of+the+company%26%238217%3Bs+IND+application&index=2&md5=41332b86bd19bfc3167a8b2f5b89c87d" shape="rect">the FDA’s clearance of the company’s IND application</a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Four-technology%2Fmagsense-technology%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=MagSense%26%23174%3B&index=3&md5=5d7326bd693feba178dbdd8ba2d94fec" shape="rect">MagSense®</a> imaging agent in HER2+ breast cancer. The company has already begun <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fclinical-trials%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=trial+activation+activities&index=4&md5=6f0e1d9ad5421e49076926e889cb0b9e" shape="rect">trial activation activities</a> and expects to begin patient recruitment later this year. </p><p> “We are very pleased with the strong demand we saw http://www.streetinsider.com/Press+Releases/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html Thu, 25 Jun 2026 11:51:00 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial http://www.streetinsider.com/Press+Releases/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html <p> MELBOURNE, Australia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.imagionbiosystems.com&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=Imagion+Biosystems%2C+Ltd.+%28ASX%3A+IBX%29&index=1&md5=681842b3cfdaae4cd61f68c1e5edcaa5" shape="rect">Imagion Biosystems, Ltd. (ASX: IBX)</a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fnews%2Fimagion-biosystems-ind-application-for-phase-2-trial-clears-fda-review%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=the+FDA%26%238217%3Bs+clearance+of+the+company%26%238217%3Bs+IND+application&index=2&md5=41332b86bd19bfc3167a8b2f5b89c87d" shape="rect">the FDA’s clearance of the company’s IND application</a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Four-technology%2Fmagsense-technology%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=MagSense%26%23174%3B&index=3&md5=5d7326bd693feba178dbdd8ba2d94fec" shape="rect">MagSense®</a> imaging agent in HER2+ breast cancer. The company has already begun <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fclinical-trials%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=trial+activation+activities&index=4&md5=6f0e1d9ad5421e49076926e889cb0b9e" shape="rect">trial activation activities</a> and expects to begin patient recruitment later this year. </p><p> “We are very pleased with the strong demand we saw http://www.streetinsider.com/Press+Releases/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html Thu, 25 Jun 2026 11:51:00 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial http://www.streetinsider.com/Press+Releases/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html <p> MELBOURNE, Australia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.imagionbiosystems.com&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=Imagion+Biosystems%2C+Ltd.+%28ASX%3A+IBX%29&index=1&md5=681842b3cfdaae4cd61f68c1e5edcaa5" shape="rect">Imagion Biosystems, Ltd. (ASX: IBX)</a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fnews%2Fimagion-biosystems-ind-application-for-phase-2-trial-clears-fda-review%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=the+FDA%26%238217%3Bs+clearance+of+the+company%26%238217%3Bs+IND+application&index=2&md5=41332b86bd19bfc3167a8b2f5b89c87d" shape="rect">the FDA’s clearance of the company’s IND application</a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Four-technology%2Fmagsense-technology%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=MagSense%26%23174%3B&index=3&md5=5d7326bd693feba178dbdd8ba2d94fec" shape="rect">MagSense®</a> imaging agent in HER2+ breast cancer. The company has already begun <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fclinical-trials%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=trial+activation+activities&index=4&md5=6f0e1d9ad5421e49076926e889cb0b9e" shape="rect">trial activation activities</a> and expects to begin patient recruitment later this year. </p><p> “We are very pleased with the strong demand we saw http://www.streetinsider.com/Press+Releases/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html Thu, 25 Jun 2026 11:51:00 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial http://www.streetinsider.com/Business+Wire/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html <p> MELBOURNE, Australia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.imagionbiosystems.com&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=Imagion+Biosystems%2C+Ltd.+%28ASX%3A+IBX%29&index=1&md5=681842b3cfdaae4cd61f68c1e5edcaa5" shape="rect">Imagion Biosystems, Ltd. (ASX: IBX)</a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fnews%2Fimagion-biosystems-ind-application-for-phase-2-trial-clears-fda-review%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=the+FDA%26%238217%3Bs+clearance+of+the+company%26%238217%3Bs+IND+application&index=2&md5=41332b86bd19bfc3167a8b2f5b89c87d" shape="rect">the FDA’s clearance of the company’s IND application</a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Four-technology%2Fmagsense-technology%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=MagSense%26%23174%3B&index=3&md5=5d7326bd693feba178dbdd8ba2d94fec" shape="rect">MagSense®</a> imaging agent in HER2+ breast cancer. The company has already begun <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fclinical-trials%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=trial+activation+activities&index=4&md5=6f0e1d9ad5421e49076926e889cb0b9e" shape="rect">trial activation activities</a> and expects to begin patient recruitment later this year. </p><p> “We are very pleased with the strong demand we saw http://www.streetinsider.com/Business+Wire/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html Thu, 25 Jun 2026 11:51:00 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial http://www.streetinsider.com/Business+Wire/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html <p> MELBOURNE, Australia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.imagionbiosystems.com&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=Imagion+Biosystems%2C+Ltd.+%28ASX%3A+IBX%29&index=1&md5=681842b3cfdaae4cd61f68c1e5edcaa5" shape="rect">Imagion Biosystems, Ltd. (ASX: IBX)</a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fnews%2Fimagion-biosystems-ind-application-for-phase-2-trial-clears-fda-review%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=the+FDA%26%238217%3Bs+clearance+of+the+company%26%238217%3Bs+IND+application&index=2&md5=41332b86bd19bfc3167a8b2f5b89c87d" shape="rect">the FDA’s clearance of the company’s IND application</a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Four-technology%2Fmagsense-technology%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=MagSense%26%23174%3B&index=3&md5=5d7326bd693feba178dbdd8ba2d94fec" shape="rect">MagSense®</a> imaging agent in HER2+ breast cancer. The company has already begun <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fclinical-trials%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=trial+activation+activities&index=4&md5=6f0e1d9ad5421e49076926e889cb0b9e" shape="rect">trial activation activities</a> and expects to begin patient recruitment later this year. </p><p> “We are very pleased with the strong demand we saw http://www.streetinsider.com/Business+Wire/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html Thu, 25 Jun 2026 11:51:00 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial http://www.streetinsider.com/Business+Wire/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html <p> MELBOURNE, Australia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.imagionbiosystems.com&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=Imagion+Biosystems%2C+Ltd.+%28ASX%3A+IBX%29&index=1&md5=681842b3cfdaae4cd61f68c1e5edcaa5" shape="rect">Imagion Biosystems, Ltd. (ASX: IBX)</a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fnews%2Fimagion-biosystems-ind-application-for-phase-2-trial-clears-fda-review%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=the+FDA%26%238217%3Bs+clearance+of+the+company%26%238217%3Bs+IND+application&index=2&md5=41332b86bd19bfc3167a8b2f5b89c87d" shape="rect">the FDA’s clearance of the company’s IND application</a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Four-technology%2Fmagsense-technology%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=MagSense%26%23174%3B&index=3&md5=5d7326bd693feba178dbdd8ba2d94fec" shape="rect">MagSense®</a> imaging agent in HER2+ breast cancer. The company has already begun <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fclinical-trials%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=trial+activation+activities&index=4&md5=6f0e1d9ad5421e49076926e889cb0b9e" shape="rect">trial activation activities</a> and expects to begin patient recruitment later this year. </p><p> “We are very pleased with the strong demand we saw http://www.streetinsider.com/Business+Wire/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html Thu, 25 Jun 2026 11:51:00 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial http://www.streetinsider.com/Business+Wire/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html <p> MELBOURNE, Australia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.imagionbiosystems.com&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=Imagion+Biosystems%2C+Ltd.+%28ASX%3A+IBX%29&index=1&md5=681842b3cfdaae4cd61f68c1e5edcaa5" shape="rect">Imagion Biosystems, Ltd. (ASX: IBX)</a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fnews%2Fimagion-biosystems-ind-application-for-phase-2-trial-clears-fda-review%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=the+FDA%26%238217%3Bs+clearance+of+the+company%26%238217%3Bs+IND+application&index=2&md5=41332b86bd19bfc3167a8b2f5b89c87d" shape="rect">the FDA’s clearance of the company’s IND application</a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Four-technology%2Fmagsense-technology%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=MagSense%26%23174%3B&index=3&md5=5d7326bd693feba178dbdd8ba2d94fec" shape="rect">MagSense®</a> imaging agent in HER2+ breast cancer. The company has already begun <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fclinical-trials%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=trial+activation+activities&index=4&md5=6f0e1d9ad5421e49076926e889cb0b9e" shape="rect">trial activation activities</a> and expects to begin patient recruitment later this year. </p><p> “We are very pleased with the strong demand we saw http://www.streetinsider.com/Business+Wire/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html Thu, 25 Jun 2026 11:51:00 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial http://www.streetinsider.com/Business+Wire/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html <p> MELBOURNE, Australia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.imagionbiosystems.com&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=Imagion+Biosystems%2C+Ltd.+%28ASX%3A+IBX%29&index=1&md5=681842b3cfdaae4cd61f68c1e5edcaa5" shape="rect">Imagion Biosystems, Ltd. (ASX: IBX)</a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fnews%2Fimagion-biosystems-ind-application-for-phase-2-trial-clears-fda-review%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=the+FDA%26%238217%3Bs+clearance+of+the+company%26%238217%3Bs+IND+application&index=2&md5=41332b86bd19bfc3167a8b2f5b89c87d" shape="rect">the FDA’s clearance of the company’s IND application</a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Four-technology%2Fmagsense-technology%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=MagSense%26%23174%3B&index=3&md5=5d7326bd693feba178dbdd8ba2d94fec" shape="rect">MagSense®</a> imaging agent in HER2+ breast cancer. The company has already begun <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimagionbiosystems.com%2Fclinical-trials%2F&esheet=54560330&newsitemid=20260625573810&lan=en-US&anchor=trial+activation+activities&index=4&md5=6f0e1d9ad5421e49076926e889cb0b9e" shape="rect">trial activation activities</a> and expects to begin patient recruitment later this year. </p><p> “We are very pleased with the strong demand we saw http://www.streetinsider.com/Business+Wire/Imagion+Biosystems+Secures+AU%243.75M+in+Capital+Raise+Following+FDA+Clearance+of+Phase+2+Clinical+Trial/26690356.html Thu, 25 Jun 2026 11:51:00 -0400 A.12119623 A.30032959 IBX O.09898189 O.11217927 Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html <p>MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="http://EmergingGrowth.com">EmergingGrowth.com</a> a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026.</p> <p>The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=V4Ud4kxYYYplPuKIZ4K7yFySJbPprSu1PtJpLprx13NEG1mnt3vMgWYUEDhNx86DTsGk-CXgZRRCs6ewf_kAXrwiMhKTH2d1dlIcJ5V0itL2_XkODDvQ_e23dfUu37XyJMy8se1aHE_0pDqGq_U720eqoRqjOLzE8xM57v228qooGaQnQD7L7bhT86OqLhEn" rel="nofollow" target="_blank">Register for the Conference here.</a></p> <p>Submit Questions for any of the presenting companies to: <br/><a target="_blank" href="https://www.globenewswire.com/Tracker?data=-toNGomsOWsCMrhiIJK6HPR-wCSRLnC0glMNc4sKAt096EEKM8tcyBIMngguKvSWGe1TaRCQa4Lwig3LLAodeX97n67Qo8vJ8ZDK3W0NHuBIm74OCNkz9slIXEnB4RGc" rel="nofollow" target="_blank">Questions@EmergingGrowth.com</a></p> <p>For updates, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1HTzfMum5WZXcwGZp_kChJOZq3KbwT2NdPdfqxruo5L1_TT3-LW9V5u1TiKDKKbqJyfKptdxOAT4T8_vRsylJtpJ6cIt9jFVYFTPl17MKtGxwa2KMAjtyIZGNiX3CF-s" rel="nofollow" target="_blank">follow us http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html Tue, 09 Jun 2026 07:00:00 -0400 A.50205019 A.50209383 ADK AFDG AFDGD CIA DGNOF HDRSF HI IBX IMTCF INTR JAGX JUNS KGLDF KING O.00100155 O.00610402 O.00706867 O.02535360 O.02579079 O.02602712 O.04886050 O.05127747 O.06565485 O.11383686 O.17570912 O.26335792 O.31275575 O.38320198 O.51214308 O.52729045 O.53819132 O.54692168 O.57577849 O.68992447 ONEI PDC QNI QNICF SKHRF SRC TCF TRLEF USAU VGZ VWAV ZENA Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html <p>MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="http://EmergingGrowth.com">EmergingGrowth.com</a> a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026.</p> <p>The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=V4Ud4kxYYYplPuKIZ4K7yFySJbPprSu1PtJpLprx13NEG1mnt3vMgWYUEDhNx86DTsGk-CXgZRRCs6ewf_kAXrwiMhKTH2d1dlIcJ5V0itL2_XkODDvQ_e23dfUu37XyJMy8se1aHE_0pDqGq_U720eqoRqjOLzE8xM57v228qooGaQnQD7L7bhT86OqLhEn" rel="nofollow" target="_blank">Register for the Conference here.</a></p> <p>Submit Questions for any of the presenting companies to: <br/><a target="_blank" href="https://www.globenewswire.com/Tracker?data=-toNGomsOWsCMrhiIJK6HPR-wCSRLnC0glMNc4sKAt096EEKM8tcyBIMngguKvSWGe1TaRCQa4Lwig3LLAodeX97n67Qo8vJ8ZDK3W0NHuBIm74OCNkz9slIXEnB4RGc" rel="nofollow" target="_blank">Questions@EmergingGrowth.com</a></p> <p>For updates, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1HTzfMum5WZXcwGZp_kChJOZq3KbwT2NdPdfqxruo5L1_TT3-LW9V5u1TiKDKKbqJyfKptdxOAT4T8_vRsylJtpJ6cIt9jFVYFTPl17MKtGxwa2KMAjtyIZGNiX3CF-s" rel="nofollow" target="_blank">follow us http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html Tue, 09 Jun 2026 07:00:00 -0400 A.50205019 A.50209383 ADK AFDG AFDGD CIA DGNOF HDRSF HI IBX IMTCF INTR JAGX JUNS KGLDF KING O.00100155 O.00610402 O.00706867 O.02535360 O.02579079 O.02602712 O.04886050 O.05127747 O.06565485 O.11383686 O.17570912 O.26335792 O.31275575 O.38320198 O.51214308 O.52729045 O.53819132 O.54692168 O.57577849 O.68992447 ONEI PDC QNI QNICF SKHRF SRC TCF TRLEF USAU VGZ VWAV ZENA Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html <p>MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="http://EmergingGrowth.com">EmergingGrowth.com</a> a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026.</p> <p>The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=V4Ud4kxYYYplPuKIZ4K7yFySJbPprSu1PtJpLprx13NEG1mnt3vMgWYUEDhNx86DTsGk-CXgZRRCs6ewf_kAXrwiMhKTH2d1dlIcJ5V0itL2_XkODDvQ_e23dfUu37XyJMy8se1aHE_0pDqGq_U720eqoRqjOLzE8xM57v228qooGaQnQD7L7bhT86OqLhEn" rel="nofollow" target="_blank">Register for the Conference here.</a></p> <p>Submit Questions for any of the presenting companies to: <br/><a target="_blank" href="https://www.globenewswire.com/Tracker?data=-toNGomsOWsCMrhiIJK6HPR-wCSRLnC0glMNc4sKAt096EEKM8tcyBIMngguKvSWGe1TaRCQa4Lwig3LLAodeX97n67Qo8vJ8ZDK3W0NHuBIm74OCNkz9slIXEnB4RGc" rel="nofollow" target="_blank">Questions@EmergingGrowth.com</a></p> <p>For updates, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1HTzfMum5WZXcwGZp_kChJOZq3KbwT2NdPdfqxruo5L1_TT3-LW9V5u1TiKDKKbqJyfKptdxOAT4T8_vRsylJtpJ6cIt9jFVYFTPl17MKtGxwa2KMAjtyIZGNiX3CF-s" rel="nofollow" target="_blank">follow us http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html Tue, 09 Jun 2026 07:00:00 -0400 A.50205019 A.50209383 ADK AFDG AFDGD CIA DGNOF HDRSF HI IBX IMTCF INTR JAGX JUNS KGLDF KING O.00100155 O.00610402 O.00706867 O.02535360 O.02579079 O.02602712 O.04886050 O.05127747 O.06565485 O.11383686 O.17570912 O.26335792 O.31275575 O.38320198 O.51214308 O.52729045 O.53819132 O.54692168 O.57577849 O.68992447 ONEI PDC QNI QNICF SKHRF SRC TCF TRLEF USAU VGZ VWAV ZENA Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html <p>MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="http://EmergingGrowth.com">EmergingGrowth.com</a> a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026.</p> <p>The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=V4Ud4kxYYYplPuKIZ4K7yFySJbPprSu1PtJpLprx13NEG1mnt3vMgWYUEDhNx86DTsGk-CXgZRRCs6ewf_kAXrwiMhKTH2d1dlIcJ5V0itL2_XkODDvQ_e23dfUu37XyJMy8se1aHE_0pDqGq_U720eqoRqjOLzE8xM57v228qooGaQnQD7L7bhT86OqLhEn" rel="nofollow" target="_blank">Register for the Conference here.</a></p> <p>Submit Questions for any of the presenting companies to: <br/><a target="_blank" href="https://www.globenewswire.com/Tracker?data=-toNGomsOWsCMrhiIJK6HPR-wCSRLnC0glMNc4sKAt096EEKM8tcyBIMngguKvSWGe1TaRCQa4Lwig3LLAodeX97n67Qo8vJ8ZDK3W0NHuBIm74OCNkz9slIXEnB4RGc" rel="nofollow" target="_blank">Questions@EmergingGrowth.com</a></p> <p>For updates, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1HTzfMum5WZXcwGZp_kChJOZq3KbwT2NdPdfqxruo5L1_TT3-LW9V5u1TiKDKKbqJyfKptdxOAT4T8_vRsylJtpJ6cIt9jFVYFTPl17MKtGxwa2KMAjtyIZGNiX3CF-s" rel="nofollow" target="_blank">follow us http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html Tue, 09 Jun 2026 07:00:00 -0400 A.50205019 A.50209383 ADK AFDG AFDGD CIA DGNOF HDRSF HI IBX IMTCF INTR JAGX JUNS KGLDF KING O.00100155 O.00610402 O.00706867 O.02535360 O.02579079 O.02602712 O.04886050 O.05127747 O.06565485 O.11383686 O.17570912 O.26335792 O.31275575 O.38320198 O.51214308 O.52729045 O.53819132 O.54692168 O.57577849 O.68992447 ONEI PDC QNI QNICF SKHRF SRC TCF TRLEF USAU VGZ VWAV ZENA Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html <p>MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="http://EmergingGrowth.com">EmergingGrowth.com</a> a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026.</p> <p>The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=V4Ud4kxYYYplPuKIZ4K7yFySJbPprSu1PtJpLprx13NEG1mnt3vMgWYUEDhNx86DTsGk-CXgZRRCs6ewf_kAXrwiMhKTH2d1dlIcJ5V0itL2_XkODDvQ_e23dfUu37XyJMy8se1aHE_0pDqGq_U720eqoRqjOLzE8xM57v228qooGaQnQD7L7bhT86OqLhEn" rel="nofollow" target="_blank">Register for the Conference here.</a></p> <p>Submit Questions for any of the presenting companies to: <br/><a target="_blank" href="https://www.globenewswire.com/Tracker?data=-toNGomsOWsCMrhiIJK6HPR-wCSRLnC0glMNc4sKAt096EEKM8tcyBIMngguKvSWGe1TaRCQa4Lwig3LLAodeX97n67Qo8vJ8ZDK3W0NHuBIm74OCNkz9slIXEnB4RGc" rel="nofollow" target="_blank">Questions@EmergingGrowth.com</a></p> <p>For updates, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1HTzfMum5WZXcwGZp_kChJOZq3KbwT2NdPdfqxruo5L1_TT3-LW9V5u1TiKDKKbqJyfKptdxOAT4T8_vRsylJtpJ6cIt9jFVYFTPl17MKtGxwa2KMAjtyIZGNiX3CF-s" rel="nofollow" target="_blank">follow us http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html Tue, 09 Jun 2026 07:00:00 -0400 A.50205019 A.50209383 ADK AFDG AFDGD CIA DGNOF HDRSF HI IBX IMTCF INTR JAGX JUNS KGLDF KING O.00100155 O.00610402 O.00706867 O.02535360 O.02579079 O.02602712 O.04886050 O.05127747 O.06565485 O.11383686 O.17570912 O.26335792 O.31275575 O.38320198 O.51214308 O.52729045 O.53819132 O.54692168 O.57577849 O.68992447 ONEI PDC QNI QNICF SKHRF SRC TCF TRLEF USAU VGZ VWAV ZENA Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html <p>MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="http://EmergingGrowth.com">EmergingGrowth.com</a> a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026.</p> <p>The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=V4Ud4kxYYYplPuKIZ4K7yFySJbPprSu1PtJpLprx13NEG1mnt3vMgWYUEDhNx86DTsGk-CXgZRRCs6ewf_kAXrwiMhKTH2d1dlIcJ5V0itL2_XkODDvQ_e23dfUu37XyJMy8se1aHE_0pDqGq_U720eqoRqjOLzE8xM57v228qooGaQnQD7L7bhT86OqLhEn" rel="nofollow" target="_blank">Register for the Conference here.</a></p> <p>Submit Questions for any of the presenting companies to: <br/><a target="_blank" href="https://www.globenewswire.com/Tracker?data=-toNGomsOWsCMrhiIJK6HPR-wCSRLnC0glMNc4sKAt096EEKM8tcyBIMngguKvSWGe1TaRCQa4Lwig3LLAodeX97n67Qo8vJ8ZDK3W0NHuBIm74OCNkz9slIXEnB4RGc" rel="nofollow" target="_blank">Questions@EmergingGrowth.com</a></p> <p>For updates, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1HTzfMum5WZXcwGZp_kChJOZq3KbwT2NdPdfqxruo5L1_TT3-LW9V5u1TiKDKKbqJyfKptdxOAT4T8_vRsylJtpJ6cIt9jFVYFTPl17MKtGxwa2KMAjtyIZGNiX3CF-s" rel="nofollow" target="_blank">follow us http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html Tue, 09 Jun 2026 07:00:00 -0400 A.50205019 A.50209383 ADK AFDG AFDGD CIA DGNOF HDRSF HI IBX IMTCF INTR JAGX JUNS KGLDF KING O.00100155 O.00610402 O.00706867 O.02535360 O.02579079 O.02602712 O.04886050 O.05127747 O.06565485 O.11383686 O.17570912 O.26335792 O.31275575 O.38320198 O.51214308 O.52729045 O.53819132 O.54692168 O.57577849 O.68992447 ONEI PDC QNI QNICF SKHRF SRC TCF TRLEF USAU VGZ VWAV ZENA Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html <p>MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="http://EmergingGrowth.com">EmergingGrowth.com</a> a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026.</p> <p>The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=V4Ud4kxYYYplPuKIZ4K7yFySJbPprSu1PtJpLprx13NEG1mnt3vMgWYUEDhNx86DTsGk-CXgZRRCs6ewf_kAXrwiMhKTH2d1dlIcJ5V0itL2_XkODDvQ_e23dfUu37XyJMy8se1aHE_0pDqGq_U720eqoRqjOLzE8xM57v228qooGaQnQD7L7bhT86OqLhEn" rel="nofollow" target="_blank">Register for the Conference here.</a></p> <p>Submit Questions for any of the presenting companies to: <br/><a target="_blank" href="https://www.globenewswire.com/Tracker?data=-toNGomsOWsCMrhiIJK6HPR-wCSRLnC0glMNc4sKAt096EEKM8tcyBIMngguKvSWGe1TaRCQa4Lwig3LLAodeX97n67Qo8vJ8ZDK3W0NHuBIm74OCNkz9slIXEnB4RGc" rel="nofollow" target="_blank">Questions@EmergingGrowth.com</a></p> <p>For updates, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1HTzfMum5WZXcwGZp_kChJOZq3KbwT2NdPdfqxruo5L1_TT3-LW9V5u1TiKDKKbqJyfKptdxOAT4T8_vRsylJtpJ6cIt9jFVYFTPl17MKtGxwa2KMAjtyIZGNiX3CF-s" rel="nofollow" target="_blank">follow us http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html Tue, 09 Jun 2026 07:00:00 -0400 A.50205019 A.50209383 ADK AFDG AFDGD CIA DGNOF HDRSF HI IBX IMTCF INTR JAGX JUNS KGLDF KING O.00100155 O.00610402 O.00706867 O.02535360 O.02579079 O.02602712 O.04886050 O.05127747 O.06565485 O.11383686 O.17570912 O.26335792 O.31275575 O.38320198 O.51214308 O.52729045 O.53819132 O.54692168 O.57577849 O.68992447 ONEI PDC QNI QNICF SKHRF SRC TCF TRLEF USAU VGZ VWAV ZENA Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html <p>MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="http://EmergingGrowth.com">EmergingGrowth.com</a> a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026.</p> <p>The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=V4Ud4kxYYYplPuKIZ4K7yFySJbPprSu1PtJpLprx13NEG1mnt3vMgWYUEDhNx86DTsGk-CXgZRRCs6ewf_kAXrwiMhKTH2d1dlIcJ5V0itL2_XkODDvQ_e23dfUu37XyJMy8se1aHE_0pDqGq_U720eqoRqjOLzE8xM57v228qooGaQnQD7L7bhT86OqLhEn" rel="nofollow" target="_blank">Register for the Conference here.</a></p> <p>Submit Questions for any of the presenting companies to: <br/><a target="_blank" href="https://www.globenewswire.com/Tracker?data=-toNGomsOWsCMrhiIJK6HPR-wCSRLnC0glMNc4sKAt096EEKM8tcyBIMngguKvSWGe1TaRCQa4Lwig3LLAodeX97n67Qo8vJ8ZDK3W0NHuBIm74OCNkz9slIXEnB4RGc" rel="nofollow" target="_blank">Questions@EmergingGrowth.com</a></p> <p>For updates, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1HTzfMum5WZXcwGZp_kChJOZq3KbwT2NdPdfqxruo5L1_TT3-LW9V5u1TiKDKKbqJyfKptdxOAT4T8_vRsylJtpJ6cIt9jFVYFTPl17MKtGxwa2KMAjtyIZGNiX3CF-s" rel="nofollow" target="_blank">follow us http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html Tue, 09 Jun 2026 07:00:00 -0400 A.50205019 A.50209383 ADK AFDG AFDGD CIA DGNOF HDRSF HI IBX IMTCF INTR JAGX JUNS KGLDF KING O.00100155 O.00610402 O.00706867 O.02535360 O.02579079 O.02602712 O.04886050 O.05127747 O.06565485 O.11383686 O.17570912 O.26335792 O.31275575 O.38320198 O.51214308 O.52729045 O.53819132 O.54692168 O.57577849 O.68992447 ONEI PDC QNI QNICF SKHRF SRC TCF TRLEF USAU VGZ VWAV ZENA Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html <p>MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="http://EmergingGrowth.com">EmergingGrowth.com</a> a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026.</p> <p>The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=V4Ud4kxYYYplPuKIZ4K7yFySJbPprSu1PtJpLprx13NEG1mnt3vMgWYUEDhNx86DTsGk-CXgZRRCs6ewf_kAXrwiMhKTH2d1dlIcJ5V0itL2_XkODDvQ_e23dfUu37XyJMy8se1aHE_0pDqGq_U720eqoRqjOLzE8xM57v228qooGaQnQD7L7bhT86OqLhEn" rel="nofollow" target="_blank">Register for the Conference here.</a></p> <p>Submit Questions for any of the presenting companies to: <br/><a target="_blank" href="https://www.globenewswire.com/Tracker?data=-toNGomsOWsCMrhiIJK6HPR-wCSRLnC0glMNc4sKAt096EEKM8tcyBIMngguKvSWGe1TaRCQa4Lwig3LLAodeX97n67Qo8vJ8ZDK3W0NHuBIm74OCNkz9slIXEnB4RGc" rel="nofollow" target="_blank">Questions@EmergingGrowth.com</a></p> <p>For updates, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1HTzfMum5WZXcwGZp_kChJOZq3KbwT2NdPdfqxruo5L1_TT3-LW9V5u1TiKDKKbqJyfKptdxOAT4T8_vRsylJtpJ6cIt9jFVYFTPl17MKtGxwa2KMAjtyIZGNiX3CF-s" rel="nofollow" target="_blank">follow us http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html Tue, 09 Jun 2026 07:00:00 -0400 A.50205019 A.50209383 ADK AFDG AFDGD CIA DGNOF HDRSF HI IBX IMTCF INTR JAGX JUNS KGLDF KING O.00100155 O.00610402 O.00706867 O.02535360 O.02579079 O.02602712 O.04886050 O.05127747 O.06565485 O.11383686 O.17570912 O.26335792 O.31275575 O.38320198 O.51214308 O.52729045 O.53819132 O.54692168 O.57577849 O.68992447 ONEI PDC QNI QNICF SKHRF SRC TCF TRLEF USAU VGZ VWAV ZENA Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html <p>MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="http://EmergingGrowth.com">EmergingGrowth.com</a> a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026.</p> <p>The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=V4Ud4kxYYYplPuKIZ4K7yFySJbPprSu1PtJpLprx13NEG1mnt3vMgWYUEDhNx86DTsGk-CXgZRRCs6ewf_kAXrwiMhKTH2d1dlIcJ5V0itL2_XkODDvQ_e23dfUu37XyJMy8se1aHE_0pDqGq_U720eqoRqjOLzE8xM57v228qooGaQnQD7L7bhT86OqLhEn" rel="nofollow" target="_blank">Register for the Conference here.</a></p> <p>Submit Questions for any of the presenting companies to: <br/><a target="_blank" href="https://www.globenewswire.com/Tracker?data=-toNGomsOWsCMrhiIJK6HPR-wCSRLnC0glMNc4sKAt096EEKM8tcyBIMngguKvSWGe1TaRCQa4Lwig3LLAodeX97n67Qo8vJ8ZDK3W0NHuBIm74OCNkz9slIXEnB4RGc" rel="nofollow" target="_blank">Questions@EmergingGrowth.com</a></p> <p>For updates, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1HTzfMum5WZXcwGZp_kChJOZq3KbwT2NdPdfqxruo5L1_TT3-LW9V5u1TiKDKKbqJyfKptdxOAT4T8_vRsylJtpJ6cIt9jFVYFTPl17MKtGxwa2KMAjtyIZGNiX3CF-s" rel="nofollow" target="_blank">follow us http://www.streetinsider.com/Press+Releases/Presenting+on+Emerging+Growth+Conference+93+Day+1+on+June+10%3B+Register+to+live+stream/26620051.html Tue, 09 Jun 2026 07:00:00 -0400 A.50205019 A.50209383 ADK AFDG AFDGD CIA DGNOF HDRSF HI IBX IMTCF INTR JAGX JUNS KGLDF KING O.00100155 O.00610402 O.00706867 O.02535360 O.02579079 O.02602712 O.04886050 O.05127747 O.06565485 O.11383686 O.17570912 O.26335792 O.31275575 O.38320198 O.51214308 O.52729045 O.53819132 O.54692168 O.57577849 O.68992447 ONEI PDC QNI QNICF SKHRF SRC TCF TRLEF USAU VGZ VWAV ZENA